SKB BIO-B(06990),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06990 SKB BIO-B

Market Closed 09-06 16:00:00

169.600

+0.000

0.00%

High169.600	Low169.600	Vol0.00
Open169.600	D1 Closing169.600	Amplitude0.00%
Mkt Cap37.79B	Tradable Cap22.05B	Total Shares222.84M
T/O44.48M	T/O Rate0.00%	Tradable Shares130.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"SKB BIO-B","latestPrice":169.6,"timestamp":1725609600000,"preClose":169.6,"halted":0,"volume":0,"delay":0,"floatShares":130000000,"shares":222844099,"eps":-3.1248312501675994,"marketStatus":"Market Closed","change":0,"latestTime":"09-06 16:00:00","open":169.6,"high":169.6,"low":169.6,"amount":44479908.25,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.9424842486241249,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1725845400000},"marketStatusCode":7,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":169.6,"openAndCloseTimeList":[[1725586200000,1725595200000],[1725598800000,1725609600000]],"volumeRatio":1.0958258036426278,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990","defaultTab":"news","newsList":[{"id":"2465581810","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical To Subscribe For Structured Deposit","url":"https://stock-news.laohu8.com/highlight/detail?id=2465581810","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465581810?lang=en_us&edition=fundamental","pubTime":"2024-09-05 01:34","pubTimestamp":1725471296,"startTime":"0","endTime":"0","summary":"Sept 4 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd   :   * AGREED TO SUBSCRIBE FOR STRUCTURED DEPOSIT FROM BANK OF CHENGDU FOR RMB200 MILLION Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2464377428","title":"Sichuan Kelun-Biotech Subscribes for BoCD's Structured Deposit for 200 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2464377428","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464377428?lang=en_us&edition=fundamental","pubTime":"2024-09-04 21:01","pubTimestamp":1725454863,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  subscribed for a unit structured deposit from Bank of Chengdu  for a principal amount of 200 million yuan, a Wednesday filing with the Hong Kong Exchange said.The structured deposit type is principal-guaranteed with a floating return. And it has an expected floating return rate between 1.54% and 2.70% per annum, with the bank guaranteeing a minimum 1.54% return rate.The deposit's term is 115 days starting on Sept. 6 and expiring on Dec. 30.The company has already subscribed for two other BoCD's structured deposits, bringing the total subscription amount to 450 million yuan.The company's shares were up nearly 2% on Wednesday's close.Price : $168.90, Change: $+2.5, Percent Change: +1.50%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0196878994.USD","BK1161","BK4526","BK4023","BK4585","HKD","BK0278","06990","BK4588","601838"],"gpt_icon":0},{"id":"2464716883","title":"Sichuan Kelun-Biotech Biopharmaceutical - Agreed to Subscribe for Structured Deposit From Bank of Chengdu for RMB200 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2464716883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464716883?lang=en_us&edition=fundamental","pubTime":"2024-09-04 20:14","pubTimestamp":1725452052,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240904:nFWN3KM0XR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2461133991","title":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Beat Analyst Profit Forecasts, And Analysts Have New Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2461133991","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461133991?lang=en_us&edition=fundamental","pubTime":"2024-08-22 07:11","pubTimestamp":1724281900,"startTime":"0","endTime":"0","summary":"Shareholders of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ( HKG:6990 ) will be pleased this week, given that...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-biopharmaceutical-co-ltd-beat-analyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2460507145","title":"Sichuan Kelun-Biotech Biopharmaceutical Revises R&D Framework Agreement with Kelun Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2460507145","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460507145?lang=en_us&edition=fundamental","pubTime":"2024-08-20 18:55","pubTimestamp":1724151354,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4526","06990","SHE","BK0239","LU1064131003.USD","BK1161","BK0060","LU0196878994.USD","LU2148510915.USD","BK4585","002422","BK4588","BK4023","LU1064130708.USD","HKD"],"gpt_icon":0},{"id":"2460071124","title":"Sichuan Kelun-Biotech Biopharmaceutical Revises R&D Framework Agreement with Kelun Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2460071124","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460071124?lang=en_us&edition=fundamental","pubTime":"2024-08-20 18:55","pubTimestamp":1724151354,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  has revised its existing Auxiliary R&D Services Framework Agreement with Sichuan Kelun Pharmaceutical , a Monday filing with the Hong Kong Exchange said.The revision includes expanded service scope, adjusted pricing, and increased annual caps for the years 2024 and 2025.The company and Kelun Pharma had agreed to provide each party with auxiliary R&D services and equipment until Dec. 31, 2025. Given the requirements, the parties have agreed to extend the agreement.Under the supplemental agreement, the company will pay 19 million yuan instead of 18 million yuan to Kelun Pharma group for the provision of services and equipment for 2024, and 17 million yuan instead of 15 million yuan for 2025.The company will receive 17 million yuan instead of 16 million for 2024 from the remaining Kelun, and 18 million yuan instead of 16 million yuan for 2025.Price : $168.30, Change: $-1.1, Percent Change: -0.65%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0196878994.USD","BK1161","BK4526","BK4023","BK4585","06990","BK4588","HKD"],"gpt_icon":0},{"id":"2460802758","title":"Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$195.51 From HK$196.40, Keeps at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2460802758","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460802758?lang=en_us&edition=fundamental","pubTime":"2024-08-20 17:07","pubTimestamp":1724144826,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["HKD","BK4108","BK4006","LU0196878994.USD","BK4588","BK4505","BK4526","BK1161","MT","IQ","BK4531","BK4561","BK4552","BK4023","BK4585","06990"],"gpt_icon":0},{"id":"2460275680","title":"Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$195.51 From HK$196.40, Keeps at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2460275680","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460275680?lang=en_us&edition=fundamental","pubTime":"2024-08-20 17:07","pubTimestamp":1724144826,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) has an average rating of buy and price targets ranging from HK$126.55 to HK$246.13, according to analysts polled by Capital IQ.(MT Newswires covers e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NMR","06990"],"gpt_icon":0},{"id":"2460044793","title":"China Accepts Sichuan Kelun-Biotech's New Drug Application for Lung Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2460044793","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460044793?lang=en_us&edition=fundamental","pubTime":"2024-08-20 14:28","pubTimestamp":1724135298,"startTime":"0","endTime":"0","summary":"China's medical products administrator accepted Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990) new drug application for its sacituzumab tirumotecan drug for a type of non-small cell lung cancer,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0196878994.USD","06990","BK4588","BK4023","HKD","BK1161","BK4526","BK4585"],"gpt_icon":0},{"id":"2460038044","title":"China Accepts Sichuan Kelun-Biotech's New Drug Application for Lung Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2460038044","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460038044?lang=en_us&edition=fundamental","pubTime":"2024-08-20 14:28","pubTimestamp":1724135298,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["LU0196878994.USD","BK4023","BK4585","BK4526","HKD","06990","BK1161","BK4588"],"gpt_icon":0},{"id":"2460116046","title":"Sichuan Kelun-Biotech Turns to Profit in H1 as Revenue Jumps 32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460116046","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460116046?lang=en_us&edition=fundamental","pubTime":"2024-08-20 13:26","pubTimestamp":1724131587,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4023","BK4526","BK4588","BK4585","HKD","06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2460046956","title":"Sichuan Kelun-Biotech Turns to Profit in H1 as Revenue Jumps 32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460046956","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460046956?lang=en_us&edition=fundamental","pubTime":"2024-08-20 13:26","pubTimestamp":1724131587,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  swung to an attributable profit of 310.2 million yuan in the first half from a loss of 31.1 million yuan in the year-ago period, according to a Monday filing with the Hong Kong stock exchange.The biopharmaceutical company turned to EPS of 1.41 yuan from a loss per share of 0.17. Analysts at Visible Alpha estimated a loss per share of 1.17 yuan.Revenue grew 32% to 1.38 billion yuan from 1.05 billion yuan a year earlier. Visible Alpha analysts forecast revenue at 7.11 billion yuan.Shares slid 2% during Tuesday's afternoon trading.Price : $166.80, Change: $-2.6, Percent Change: -1.53%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06990"],"gpt_icon":0},{"id":"2460748058","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says Drug Application For Sacituzumab Tirumotecan Accepted By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2460748058","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460748058?lang=en_us&edition=fundamental","pubTime":"2024-08-19 23:00","pubTimestamp":1724079626,"startTime":"0","endTime":"0","summary":"Aug 19 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd   :   * NEW DRUG APPLICATION FOR SACITUZUMAB TIRUMOTECAN (SAC-TMT) ACCEPTED BY NMPA CHINAFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2460363350","title":"Sichuan Kelun-Biotech Biopharmaceutical - New Drug Application for Sacituzumab Tirumotecan (Sac-TMT) Accepted by Nmpa China","url":"https://stock-news.laohu8.com/highlight/detail?id=2460363350","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460363350?lang=en_us&edition=fundamental","pubTime":"2024-08-19 20:51","pubTimestamp":1724071910,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240819:nFWN3K60I1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"1185610039","title":"Stock Track | SKB BIO-B Surges 7.39% After Reporting Higher Profit and Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=1185610039","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185610039?lang=en_us&edition=fundamental","pubTime":"2024-08-19 20:08","pubTimestamp":1724069295,"startTime":"0","endTime":"0","summary":"Shares of SKB BIO-B, a biopharmaceutical company based in Sichuan, China, rallied 7.39% in intraday trading on August 19th, following the release of the company's financial results for the first half of 2024.According to the company's report, SKB BIO-B recorded a profit of RMB 310.2 million for the six-month period, representing a significant increase from the same period last year. Additionally, the company's revenue grew to RMB 1.38 billion, up from RMB 1.05 billion in the previous year.The po","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"gpt_icon":0},{"id":"2460038958","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Posts HY Profit RMB310.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2460038958","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460038958?lang=en_us&edition=fundamental","pubTime":"2024-08-19 20:05","pubTimestamp":1724069116,"startTime":"0","endTime":"0","summary":"Aug 19 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd   :   * HY PROFIT RMB310.2 MILLION   * HY REVENUE RMB1.38 BILLION VERSUS RMB1.05 BILLIONFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2460145080","title":"Sichuan Kelun-Biotech Biopharmaceutical- Hy Profit RMB310.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2460145080","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460145080?lang=en_us&edition=fundamental","pubTime":"2024-08-19 19:51","pubTimestamp":1724068291,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240819:nFWN3K60HQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2460080141","title":"Sichuan Kelun-Biotech Biopharmaceutical - Hy Revenue RMB1.38 Bln VS RMB1.05 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2460080141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460080141?lang=en_us&edition=fundamental","pubTime":"2024-08-19 19:51","pubTimestamp":1724068291,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240819:nFWN3K60HQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2457866703","title":"Private companies are Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.'s (HKG:6990) biggest owners and were rewarded after market cap rose by HK$3.3b last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2457866703","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457866703?lang=en_us&edition=fundamental","pubTime":"2024-08-07 08:26","pubTimestamp":1722990378,"startTime":"0","endTime":"0","summary":"Key Insights The considerable ownership by private companies in Sichuan Kelun-Biotech Biopharmaceutical indicates that...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/private-companies-are-sichuan-kelun-biotech-biopharmaceutica","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2454814572","title":"Sichuan Kelun-Biotech Subscribes to 250 Million Yuan Structured Deposits of Bank of Chengdu","url":"https://stock-news.laohu8.com/highlight/detail?id=2454814572","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2454814572?lang=en_us&edition=fundamental","pubTime":"2024-07-25 14:53","pubTimestamp":1721890394,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical  agreed to subscribe to Bank of Chengdu's structured deposit under two subscription agreements, with a total principal amount of 250.0 million yuan, a Wednesday filing with the Hong Kong Exchange said.On July 9, the company subscribed for the bank's principal-guaranteed with floating return type \"Fu Rong Jin Cheng\" unit structured deposit with a principal amount of 50.0 million yuan. The deposit has an expected annualized floating rate of return between 1.54% to 2.70% and it matures on Oct. 11, 2024.The company, on July 24, subscribed for the bank's principal-guaranteed with floating return type \"Fu Rong Jin Cheng\" unit structured deposit with a principal amount of 200.0 million yuan. The deposit has an expected annualized floating rate of return between 1.54% to 2.70% and it matures on Nov. 26, 2024.The company's shares were down over 1% in recent trade.Price : $148.60, Change: $-2.10, Percent Change: -1.39%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","06990","LU0196878994.USD","BK4023","HKD","BK4585","BK4588","BK4526"],"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":0.0341},{"period":"1month","weight":0.0687},{"period":"3month","weight":-0.0488},{"period":"6month","weight":0.4508},{"period":"1year","weight":1.2464},{"period":"ytd","weight":0.6482}],"compareEarnings":[{"period":"1week","weight":-0.0303},{"period":"1month","weight":0.0336},{"period":"3month","weight":-0.0502},{"period":"6month","weight":0.0667},{"period":"1year","weight":-0.0416},{"period":"ytd","weight":0.0233}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, formerly Sichuan Kelun Biotech Biopharmaceutical Co Ltd, is a China-based company mainly engaged in the research and development, production, and sales of drugs. The Company is mainly engaged in the research and development, production, and sales of biopharmaceuticals, chemical raw materials, and chemical drug formulations. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.","exchange":"SEHK","name":"SKB BIO-B","nameEN":"SKB BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.3","shortVersion":"4.26.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SKB BIO-B(06990),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SKB BIO-B(06990) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SKB BIO-B,06990,SKB BIO-B股票,SKB BIO-B股票老虎,SKB BIO-B股票老虎国际,SKB BIO-B行情,SKB BIO-B股票行情,SKB BIO-B股价,SKB BIO-B股市,SKB BIO-B股票价格,SKB BIO-B股票交易,SKB BIO-B股票购买,SKB BIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SKB BIO-B(06990),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SKB BIO-B(06990) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}